



# Storage and Handling Guide

## Guidance on Proper Preparation of mRESVIA®: Stock Storage to Administration

	CARTON OF 1 PRE-FILLED SYRINGE	CARTON OF 10 PRE-FILLED SYRINGES
<b>Frozen Storage (Stock)*</b> -40°C to -15°C (-40°F to 5°F)	Store stock product frozen	
<b>Refrigeration Thaw Duration</b> 2°C to 8°C (36°F to 46°F)	<b>60 minutes</b> Let each pre-filled syringe stand at room temperature for between 10 and 20 minutes before administering.	<b>155 minutes</b> Let each pre-filled syringe stand at room temperature for between 10 and 20 minutes before administering.
<b>Room Temperature Thaw Duration</b> 15°C to 25°C (59°F to 77°F)	<b>45 minutes</b> If mRESVIA is thawed at room temperature, the vaccine is ready to be administered.	<b>140 minutes</b> If mRESVIA is thawed at room temperature, the vaccine is ready to be administered.
<b>Storage After Thawing†</b>	<b>Refrigeration</b> 2°C to 8°C (36°F to 46°F) Beyond use date: Must not exceed 30 days	<b>OR</b> <b>Room Temperature</b> 8°C to 25°C (46°F to 77°F) Beyond use date: Must not exceed 24 hours
<b>Preparing for Use</b>	<ul style="list-style-type: none"> <li>Remove tip cap by twisting counter-clockwise until the tip cap releases. Avoid pulling the tip cap while twisting<sup>2</sup></li> <li>The pre-filled syringe may contain an air bubble; however, priming is not required. Entire volume should be injected<sup>2</sup></li> <li>Discard pre-filled syringe after use</li> </ul>	

Please ask your representative for additional guidance regarding removal of the pre-filled syringe tip cap.

\*During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

†After thawing, do not refreeze. Do not shake. Syringes should not be returned to the refrigerator after standing at room temperature.

### Indication

mRESVIA is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.

### Important Safety Information

#### Contraindications

Do not administer mRESVIA to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA.

Please see additional **IMPORTANT SAFETY INFORMATION** throughout, and scan or click the QR code on page 2 for [mRESVIA Full Prescribing Information](#).

# mRESVIA is the Only Ready-to-use RSV Vaccine in a Pre-filled Syringe



Reconstitution is not required.

## Important Safety Information (Cont.)

### Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.
- **Syncope:** Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.
- **Altered Immunocompetence:** Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.

### Adverse Reactions

In a clinical trial, the most commonly reported ( $\geq 10\%$ ) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%), and chills (11.6%).

To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or <https://vaers.hhs.gov>.



Please scan or click the QR code or ask your representative for [mRESVIA Full Prescribing Information](#).


RSV, respiratory syncytial virus.

**References:** 1. mRESVIA Prescribing Information. Moderna; 2024. 2. Data on file. Moderna, Inc.; 2024.

For Colorado and Connecticut price disclosure, please visit <https://modernadirect.com/wac-disclosure>

moderna®

© 2024 Moderna US-RSV-2400069 06/2024

 mRESVIA®  
(Respiratory Syncytial  
Virus Vaccine)